

# Gynaecological malignancies at a tertiary care centre in Mozambique

**C. Lorenzoni<sup>1,2</sup>, A. Vilajeliu<sup>5,6</sup>, C. Carrilho<sup>1,2</sup>, P. Castillo<sup>6,7</sup>, S. Barreales<sup>5</sup>, M. R. Ismail<sup>1,2</sup>, M. Sidat<sup>3</sup>, O. Augusto<sup>2</sup>, A. L. Garcia-Basteiro<sup>4,6</sup>, C. Menéndez<sup>4,6</sup>, J. Ordi<sup>6,7</sup>**

<sup>1</sup>Department of Pathology, Maputo Central Hospital, Maputo. <sup>2</sup>Faculty of Medicine, Eduardo Mondlane University, Maputo

<sup>3</sup>Department of Microbiology, Faculty of Medicine, Eduardo Mondlane University, Maputo

<sup>4</sup>Centro de Investigação em Saúde de Manhiça (CISM), Maputo (Mozambique)

<sup>5</sup>Department of Preventive Medicine and Epidemiology, Hospital Clinic, Universitat de Barcelona

<sup>6</sup>ISGlobal, Barcelona Ctr. Int. Health Res. (CRESIB), Hospital Clínic - Universitat de Barcelona, Barcelona

<sup>7</sup>Department of Pathology, Hospital Clinic, Universitat de Barcelona (Spain)

## Summary

**Objective:** To determine the frequency of gynaecological cancers over an 18-year-period in Mozambique a country located in South Eastern sub-Saharan Africa, an area in which comprehensive statistics on cancer are limited. **Materials and Methods:** Retrospective review of the pathological records of gynaecological cancers at the Maputo Central Hospital from January 1991 to December 2008. **Results:** 3,726 gynaecological cancers were reported. Malignant neoplasms of the uterine cervix (64.0% of all tumours) were the most frequent cancers, followed by breast (23.2%), vulvar-vaginal (4.1%), ovarian cancers (3.8%), cancers of the uterine corpus (3.3%), and gestational choriocarcinoma (1.7%). Tumours of the uterine cervix, vulva/vagina, uterine corpus, and ovary increased in number three times, whereas breast cancers increased five times during the study period. **Conclusions:** Malignant tumours related to human papillomavirus (HPV) accounted for over two-thirds of all malignancies. Screening for cervical cancer and vaccination against HPV should be a health priority in sub-Saharan Africa.

**Key words:** Gynaecological cancer; Cervical cancer; Human papillomavirus; Sub-Saharan Africa.

## Introduction

The cancer burden affecting a specific population is an important issue in healthcare, and the burden of the morbidity and mortality of gynaecological cancers is enormous throughout the world [1-4]. The data available from various centres worldwide are indicative of the vast geographical variability in the incidence, anatomical site, age, and stage at presentation of these cancers. While information on these parameters is available in many of the developed regions, countries of sub-Saharan Africa have irregular and limited knowledge on the incidence of cancer and the distribution of malignant tumours [2, 3, 5-9]. Indeed, data on cancer is very scarce not only in Mozambique, but also in the entire South Eastern sub-Saharan Africa, and information on the trends in cancer incidence over large periods of time in this region is exceptional.

The aim of this study was to compile and retrospectively analyse the information on gynaecological malignancies over an 18-year period (1991-2008) registered at the Maputo Central Hospital, Mozambique, which receives virtually all the specimens of Maputo City. The ultimate objective was to establish patterns of disease that could help in guiding healthcare interventions and preventive policies.

## Materials and Methods

This study was performed at the Department of Pathology of the Maputo Central Hospital (MCH), a 1,500-bed hospital that is the only tertiary healthcare facility in Mozambique. The Department receives virtually all the specimens of the city of Maputo. The Department has a database of all the samples received for pathological diagnoses including specimens of most types of cancers (with the exception of leukaemia). This study was approved by the National Bioethics Committee of Mozambique and the Mozambican Ministry of Health (Ref. 389/CNBS).

The analysis included all gynaecological cancer cases registered in the Department of Pathology of the MCH from January 1, 1991 to December 31, 2008. Data were entered into a Microsoft Access database, which, upon data entry, prevents the use of non-existent codes and performs checks for internal consistency among variables. The database was carefully reviewed (name, age) to confirm that no duplications had been registered. Information about previous analyses in the same patient was also obtained in order to identify potential duplicate registrations. Cases were identified in the registries as histological studies (including biopsies and surgical pathology), cytological specimens (aspiration or cervical scrape smears), and autopsies. All gynaecological tumours, including gestational trophoblastic neoplasms, breast cancers, primary gynaecological Kaposi sarcomas, and primary gynaecological lymphomas were included in the analysis. Multiple primary cancers occurring in the same patient were entered as separate cases. Metastases to genital organs from other primary

Revised manuscript accepted for publication January 23, 2018




Figure 1.— Sites of involvement of the 3726 gynecologic tumors identified in the Maputo Central Hospital from 1991 to 2008.




Figure 2.— Evolution of the histological types of carcinomas of the uterine cervix during the period of study.




Figure 3.— Evolution of the carcinomas of the uterine cervix and carcinomas of the breast during the period of study.

sites were excluded.

Basic demographic data were collected for each case identified, including age, gender, and address. For each specimen, the date and method of diagnosis, site from which the specimen was taken (topography), and microscopic morphology were recorded. Pa-

tient records/information were anonymized and de-identified prior to analysis. All topographic and morphologic classifications were made according to the 10<sup>th</sup> version of the International Classification of Diseases for Oncology (ICD-O). [10-12]

Data were stored in SPSS (version 18.0). Some analyses were also performed using STATA (Version 11.0). The frequency of various malignancies was determined both for the entire cohort and for specific age groups. Comparison between groups was performed using Fischer's exact test and chi square tests as applicable. Cut off for a significant *p* value was calculated using Bonferroni correction.

## Results

A total of 3,726 gynaecological cancers were diagnosed during the study period. Of these, 3,025 (81.2%) had a histological diagnosis made either on biopsy or resection specimens, 570 (15.3%) were diagnosed by fine needle aspiration biopsy or cervical cytology, and 131 (3.5%) were identified at autopsy. The mean age of the patients was  $47.7 \pm 14.2$  years. Information on age was not available in 93 women.

The cancer sites included the uterine cervix (2,383 cases, 63.9%), the breast (865, 23.2%), vagina and vulva (152, 4.1%), ovary and fallopian tube (140, 3.8%), and uterine corpus (122, 3.3%). Gestational choriocarcinoma was identified in 64 women (1.7%) (Figure 1). The absolute numbers of cases and the percentage of each gynaecological cancer in the different age groups are shown in Table 1.

Cancer of the uterine cervix was the most frequent gynaecological cancer over the entire study period in all the age groups, except in paediatric patients. The mean age of women with cervical cancer was  $47.8 \pm 13.4$  years (median 46 years). The histological types of cervical cancer are presented in Table 2. Patients between 30 and 44 years of age constituted the commonest age group affected. One hundred and ninety-five (5.7%) cervical cancers were detected in patients younger than 30 years of age. The histological types of malignant neoplasms of the uterine cervix are presented in Figure 2. Both squamous cell carcinomas and adenocarcinomas or adenosquamous carcinomas increased by over three times during the period of study (Figure 3), with no differences between both histological diagnoses.

Carcinoma of the breast was the second most frequent gynaecological malignancy, with the mean age of these patients being  $49.3 \pm 13.6$  years. Most breast tumours (829 out of 865, 95.8%) were carcinomas (either ductal or lobular). Twenty-one of the tumours were sarcomas, six arising in phyllodes tumours. Eleven malignant lymphomas and four Kaposi sarcomas were diagnosed during the study period.

Carcinomas of the vulva and vagina were most commonly squamous cell carcinomas (131 out of 152 tumours; 86.2%). Ten vaginal adenocarcinomas, three vaginal leiomyosarcomas, two Kaposi sarcomas, two verrucous carcinomas of the vulva, and one fibrosarcoma were identified. The mean age of the patients with vaginal cancer was

Table 1. — *Age at diagnosis of the different gynecological cancers. Data are presented as absolute numbers and percentages (in brackets).*

Site	Age group (years)							
	0-14	15-29	30-44	45-59	60-74	≥75	Unknown	All ages
Uterine cervix	7 (33.3)	137 (49.3)	871 (68.2)	791 (64.2)	428 (61.8)	78 (59.1)	71 (76.3)	2,383
Vagina/vulva	3 (14.3)	28 (10.1)	37 (2.9)	40 (3.2)	32 (4.6)	7 (5.3)	5 (5.4)	152
Breast	1 (4.8)	42 (15.1)	286 (22.4)	328 (26.6)	156 (22.5)	40 (30.3)	12 (12.9)	865
Ovary/tube	9 (42.9)	27 (9.7)	40 (3.1)	37 (3.0)	22 (3.2)	2 (1.5)	3 (3.2)	140
Uterine corpus	0 (0.0)	9 (3.2)	21 (1.6)	31 (2.5)	54 (7.8)	5 (3.8)	2 (2.2)	122
Trophoblast	1 (4.8)	35 (12.6)	23 (1.8)	5 (0.4)	0 (0.0)	0 (0.0)	0 (0.0)	64
Total	21	278	1,278	1,232	692	132	93	3,726

Table 2. — *Histological types of the carcinomas of the uterine cervix. Data are presented as absolute numbers and percentages (in brackets).*

	n	(%)
Squamous cell carcinoma	2107	(88.4)
Adenocarcinoma	168	(7.0)
Adenosquamous carcinoma	50	(2.1)
Undifferentiated carcinoma	29	(1.2)
Carcinosarcoma	11	(0.5)
Small cell carcinoma	7	(0.3)
Malignant lymphoma	4	(0.2)
Leiomyosarcoma	3	(0.1)
Kaposi's sarcoma	2	(0.1)
Rhabdomyosarcoma	2	(0.1)

47.2 ± 17.9 years while that of patients with vulvar cancer was 45.2 ± 16.7 years.

Women with ovarian malignancies had a mean age of 41.3 ± 18.1 years. Epithelial ovarian cancers were the most frequent tumours (114 out of 137; 83.2%). Non-epithelial neoplasms included 12 germ cell neoplasms, four sex-cord stromal cell tumours, five malignant lymphomas, and one leiomyosarcoma. Three carcinomas of the fallopian tube were identified.

Malignant tumours of the uterine corpus were mostly of epithelial origin (85 tumours, 68.0%), but 39 (32.0%) were sarcomas. The most frequent epithelial tumours was endometrioid adenocarcinoma (65 tumours; 53.3%), followed by serous/clear cell carcinomas (11 tumours, 9.0%) and carcinosarcomas (seven tumours, 5.7%). The mean age of patients with epithelial tumours was 59.8 ± 12.6 years. The mean age of patients with sarcoma was 44.4 ± 15.9 years. Women with choriocarcinoma had a mean age of 29.2 ± 10.0 years.

In the paediatric age group ( $\leq 14$  years) the ovary was the most frequent location of malignant neoplasms (nine out of 21 tumours). The histological diagnoses were germinal cell tumours in seven cases (four dysgerminomas, two immature teratomas, and one choriocarcinoma), one malignant lymphoma and one granulosa cell tumour. Other tumours included three additional malignant lymphomas

(two in the uterine cervix and one in the vagina), three rhabdomyosarcomas (uterine cervix, vagina, and vulva), a Kaposi sarcoma of the uterine cervix, a gestational choriocarcinoma, and three squamous cell carcinomas of the uterine cervix.

## Discussion

Cancer of the uterine cervix is a malignant tumour almost always associated with human papillomavirus (HPV) infection [13] and this was found to be by far the most common cancer registered in Mozambican women during the study period, representing 64.0% of all the gynaecological cancers. Cancers of the vulva and vagina, most of which were associated with HPV [14, 15], accounted for an additional 4.1% of the malignant neoplasms. Thus, in this series from Mozambique, cancers associated with HPV infection represented approximately two-thirds of all gynaecological cancers. Indeed, HPV infection has been shown to be very prevalent in Mozambique, with over 50% of the women being positive at 20 years and with a prevalence of between 20-30% in women older than 30 years of age [16-18]. These results are in agreement with previous evidence showing that cancer of the cervix is the most common cancer among African women, with the highest incidence in eastern and southern Africa [19-21]. Cervical cancers have increased during the period of study at an average of over 10% per year. Moreover, the prevalence of cancers of the uterine cervix has shown a marked increase compared with data published from the same region in the period from 1956 - 1961 (20.3 per  $10^5$  to 54.3 per  $10^5$ ). [7] In a recent community-based survey, the prevalence of HIV infection was described to be very high in Mozambique (over 45% in women older than 28 years of age) [22] and it has been proposed as the most likely explanation for a large part of the increase in the incidence of cervical cancer observed in several sub-Saharan countries. Linkage studies of HIV/AIDS and cancer registries have indicated a two- to 22-fold increase in cervical cancer in HIV-positive compared with HIV-negative women [23, 24]. However, although cervical cancer is considered to be an AIDS-defining condition, it is not clear whether the association between HIV and cervi-

cal cancer is simply due to the increased prevalence of HPV infection observed in HIV positive women as suggested by a number of studies [18, 25-30]. Squamous cell carcinoma was the predominant histological type during the study period, representing over 88% of all cervical cancers. The decline in the incidence of squamous cell carcinomas with increasing trends in adenocarcinomas observed in several western countries in which cytological screening is widely implemented [31, 32], was not observed in this population. The healthcare infrastructure in Mozambique does not support Papanicolaou or HPV testing, and cervical screening is virtually non-existent and confined to a very limited number of opportunistic examinations in a small percentage of women. A recent clinical trial in rural India found that a single round of HPV DNA testing was associated with about a 50% reduction in the risk of developing advanced cervical cancer and associated deaths, with this decrease being significantly higher than that observed with Papanicolaou testing. These findings indicate that strategies based on HPV detection are probably more adequate for low resource settings [33] and should be considered as the most appropriate alternative when screening programs are implemented. Finally, there are high expectations that cervical cancer in developing countries may be prevented by vaccines that protect against the most common oncogenic types of HPV infections (HPV types 16 and 18), which cause about 70% of cervical cancers [13], and have been shown to cause most cervical cancers in Mozambique [17]. The feasibility and acceptability of HPV immunization are currently being evaluated before national widespread implementation of this vaccine to young adolescent girls is carried out [13, 16].

Breast cancer, the most frequent neoplasm in women around the world, was the second most frequent gynaecological cancer in Mozambique, being much less prevalent than cervical cancer throughout the whole study period. Nevertheless, breast cancer increased much faster during the study period than any other gynaecological cancer. The Ugandan (Kampala) cancer registry has recently reported similar results with rates of breast cancer incidence, having nearly doubled over the past 20 years. [20] Thus, the shift in the predominance of cervical cancer to breast cancer that has occurred in developed countries [2, 3, 34] is very likely to occur in the near future in Mozambique. Indeed, although the rates still remain much lower than those in black women in the United States and several Western countries [1-4], breast cancer has already become the most commonly diagnosed cancer in women in several Sub-Saharan African countries [2, 4, 34, 35]. The reasons for the increase of this hormone-related cancer are not yet known but may include increases in the prevalence of risk factors such as early menarche, late childbearing, lower fertility, obesity, and increased awareness and detection, which are associated with urbanization and economic development.

Cancers of the ovary and uterine corpus were infrequent

in this series, representing only 3.8% and 3.3% of all the gynaecological tumours, respectively. In contrast, data from Globocan 2008 showed a much higher incidence of these tumours in most countries, particularly in Western countries [2, 3, 34]. This low incidence of these cancers in the present study can be explained, at least in part, by the low age of this population, as uterine and ovarian cancers tend to affect older patients. However, during the study period, significant increases were observed for both cancers, particularly for the cancers of the uterine corpus. Finally, gestational choriocarcinoma accounted for 1.7% of all gynaecological malignancies. This is in agreement with the decrease in prevalence reported in other countries, which has been related to improved socioeconomic conditions and dietary changes [36]. However, these results should be considered with some caution, as only cases with pathological confirmation were included in the registry and gestational trophoblastic disease can currently be diagnosed on the basis of clinical and biochemical data [37].

In summary, a significant increase in cancers in Mozambique it is found during the past two decades. Cancers related to HPV infection (cervix, vagina, and vulva) account for approximately two-thirds of all gynaecological malignancies. Widespread implementation of screening for cervical cancer and especially vaccination against HPV infection should be considered a health priority in sub-Saharan Africa since it could potentially prevent the early death of many African women. The rapid increase in the rates of breast cancer observed indicates that the emergence of cancers associated with westernization of lifestyles is likely to represent a major challenge in the near future.

## Acknowledgement

The authors are grateful to *Ministério de Saúde da República de Moçambique* and *Instituto Nacional de Estatística* for their support and collaboration. They also thank Donna Pringle for the English revision of the manuscript.

## References

- [1] Agarwal S., Malhotra K.P., Sinha S., Rajaram S.: "Profile of gynaecological malignancies reported at a tertiary care center in India over the past decade: comparative evaluation with international data". *Indian J. Cancer*, 2012, 49, 298.
- [2] Bray F., Jemal A., Grey N., Ferlay J., Forman D.: "Global cancer transitions according to the Human Development Index (2008-2030): a population-based study". *Lancet Oncol.*, 2012, 13, 790.
- [3] Ferlay J., Shin H.R., Bray F., Forman D.: "GLOBOCAN 2008: Cancer Incidence, mortality and prevalence worldwide in 2008". *Int. J. Cancer*, 2010, 127, 2893.
- [4] Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D.: "Global cancer statistics". *CA. Cancer J. Clin.*, 2011, 61, 69.
- [5] Amegbor K., Alfa A.K., Darre T., Napo-Koura G.A., Akpadza K.: "Epidemiological and pathological aspects of the gynecological and mammary cancers in Togo". *Med. Trop. (Mars.)*, 2011, 71, 451.
- [6] Jemal A., Bray F., Forman D., O'Brien M., Ferlay J., Center M., et al.: "Cancer burden in Africa and opportunities for prevention". *Cancer*

- 2012, 118, 4372.
- [7] Prates M.D., Torres F.O.: "A cancer survey in Lourenco Marques, Portuguese East Africa". *J. Natl. Cancer Inst.*, 1965, 35, 729.
- [8] Ugwu E.O., Iferikigwe E.S., Okeke T.C., Ugwu A.O., Okezie O.A., Agu P.U.: "Pattern of gynaecological cancers in University of Nigeria Teaching Hospital, Enugu, south eastern Nigeria". *Niger. J. Med.*, 2011, 20, 266.
- [9] Lorenzoni C., Vilajeliu A., Carrilho C., Ismail M.R., Castillo P., Augusto O., et al.: "Trends in Cancer Incidence in Maputo, Mozambique, 1991-2008". *PLoS One*, 2015, 10, e0130469.
- [10] Fritz A., Percy C., Jack A.: "International classification of diseases for oncology (3<sup>rd</sup> ed)". Geneva: World Health Organization, 2000.
- [11] Percy C., Van Holten V., Muir C.: "International classification of diseases for oncology". (2<sup>nd</sup> ed). Geneva: World Health Organization, 1990.
- [12] World Health Organization: "International statistical classification of diseases and related health problems". (10<sup>th</sup> revision ed). Geneva: World Health Organization, 1992.
- [13] de Sanjose S., Quint W.G., Alemany L., Geraets D.T., Klaustermeier J.E., Lloveras B., et al.: "Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study". *Lancet Oncol.*, 2010, 11, 1048.
- [14] de Sanjose S., Alemany L., Ordi J., Tous S., Alejo M., Bigby S.M., et al.: "Worldwide human papillomavirus genotype attribution in over 2000 cases of intraepithelial and invasive lesions of the vulva". *Eur. J. Cancer*, 2013, 49, 3450.
- [15] del Pino M, Rodriguez-Carunchio L, Ordi J. Pathways of vulvar intraepithelial neoplasia and squamous cell carcinoma. *Histopathology* 2013; 62: 161-175.
- [16] Kane MA, Serrano B, de Sanjose S, Wittet S. Implementation of human papillomavirus immunization in the developing world. *Vaccine* 2012; 30 Suppl 5:F192-200.
- [17] Menendez C, Castellsague X, Renom M, Sacarlal J, Quintó L, Lloveras B, et al. Prevalence and risk factors of sexually transmitted infections and cervical neoplasia in women from a rural area of southern Mozambique. *Infect Dis. Obstet. Gynecol.* 2010; 2010. pii: 609315.
- [18] Watson-Jones D, Baisley K, Brown J, Kavishe B, Andreasen A., Changalucha J, et al.: "High prevalence and incidence of human papillomavirus in a cohort of healthy young African female subjects". *Sex. Transm. Infect.*, 2013, 89, 358.
- [19] Parkin D.M., Sitas F., Chirenje M., Stein L., Abratt R., Wabinga H.: "Part I: Cancer in Indigenous Africans—burden, distribution, and trends". *Lancet Oncol.*, 2008, 9, 683.
- [20] Parkin D.M., Nambooze S., Wabwire-Mangen F., Wabinga H.R.: "Changing cancer incidence in Kampala, Uganda, 1991-2006". *Int. J. Cancer*, 2010, 126, 1187.
- [21] Sitas F., Parkin D.M., Chirenje M., Stein L., Abratt R., Wabinga H.: "Part II: Cancer in Indigenous Africans—causes and control". *Lancet Oncol.*, 2008, 9, 786.
- [22] Gonzalez R., Munguambe K., Aponte J., Bavo C., Nhalungo D., Macete E., et al.: "High HIV prevalence in a southern semi-rural area of Mozambique: a community-based survey". *HIV Med.*, 2012, 13, 581.
- [23] Denny L.A., Franceschi S., de Sanjose S., Heard I., Moscicki A.B., Palefsky J.: "Human papillomavirus, human immunodeficiency virus and immunosuppression". *Vaccine*, 2012, 30 , F168.
- [24] Stein L., Urban M.I., O'Connell D., Yu X.Q., Beral V., Newton R., et al.: "The spectrum of human immunodeficiency virus-associated cancers in a South African black population: results from a case-control study, 1995-2004". *Int. J. Cancer*, 2008, 122, 2260.
- [25] Moodley M.: "Reduction in prevalence of invasive cervical cancer in KwaZulu-Natal, South Africa: impact of the human immunodeficiency virus epidemic". *Int. J. Gynecol. Cancer*, 2006, 16, 1036.
- [26] Lomalisa P., Smith T., Guidozzi F.: "Human immunodeficiency virus infection and invasive cervical cancer in South Africa". *Gynecol. Oncol.*, 2000, 77, 460.
- [27] ter Meulen J., Eberhardt H.C., Luande J., Mgaya H.N., Chang-Claude J., Mtiro H., et al.: "Human papillomavirus (HPV) infection, HIV infection and cervical cancer in Tanzania, east Africa". *Int. J. Cancer*, 1992, 51, 515.
- [28] Mbulaiteye S.M., Bhatia K., Adebamowo C., Sasco A.J.: "HIV and cancer in Africa: mutual collaboration between HIV and cancer programs may provide timely research and public health data". *Infect. Agent. Cancer*, 2011, 6, 16.
- [29] De Vuyst H., Ndirangu G., Moodley M., Tenet V., Estambale B., Meijer C.J., et al.: "Prevalence of human papillomavirus in women with invasive cervical carcinoma by HIV status in Kenya and South Africa". *Int. J. Cancer*, 2012, 131, 949.
- [30] Moodley J.R., Hoffman M., Carrara H., Allan B.R., Cooper D.D., Rosenberg L., et al.: "HIV and pre-neoplastic and neoplastic lesions of the cervix in South Africa: a case-control study". *BMC Cancer*, 2006, 6, 135.
- [31] Vizcaino A.P., Moreno V., Bosch F.X., Muñoz N., Barros-Dios X.M., Parkin D.M.: "International trends in the incidence of cervical cancer: I. Adenocarcinoma and adenosquamous cell carcinomas". *Int. J. Cancer*, 1998, 75, 536.
- [32] Ward K.K., Shah N.R., Saenz C.C., McHale M.T., Alvarez E.A., Plaxe S.C.: "Changing demographics of cervical cancer in the United States (1973-2008)". *Gynecol. Oncol.*, 2012, 126, 330.
- [33] Sankaranarayanan R., Nene B.M., Shastri S.S., Jayant K., Muwonge R., Budukh A.M., et al.: "HPV screening for cervical cancer in rural India". *N. Engl. J. Med.*, 2009, 360, 1385.
- [34] Bray F., Ren J.S., Masuyer E., Ferlay J.: "Global estimates of cancer prevalence for 27 sites in the adult population in 2008". *Int. J. Cancer*, 2013, 132, 1133.
- [35] Youlden D.R., Cramb S.M., Dunn N.A., Muller J.M., Pyke C.M., Baade P.D.: "The descriptive epidemiology of female breast cancer: an international comparison of screening, incidence, survival and mortality". *Cancer Epidemiol.*, 2012, 36, 237.
- [36] Seckl M.J., Sebire N.J., Berkowitz R.S.: "Gestational trophoblastic disease". *Lancet*, 2010, 376, 717.
- [37] Goldstein D.P., Berkowitz R.S.: "Current management of gestational trophoblastic neoplasia". *Hematol. Oncol. Clin. North. Am.*, 2012, 26, 111.

## Corresponding Author:

J. ORDI, M.D., PhD

Department of Pathology

ISGlobal (Instituto de Salud Global) Hospital Clínic

University of Barcelona Faculty of Medicine

Villarroel 170

08036. Barcelona (Spain)

e-mail: jordi@clinic.ub.es